2014 BIO CEO & Investor Conference in New York on Tuesday, February
11, 2014 at 1:00 p.m. ET.
2014 Leerink Global Healthcare Conference in New York on Wednesday,
February 12, 2014 at 1:25 p.m. ET.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine
platform company developing targeted and programmable therapeutics
called AccurinsTM, announced today that Scott Minick, BINDís
President and CEO, is scheduled to present at the following healthcare
conferences during February 2014:
Interested parties may access a live webcast of the presentations by
visiting the BIND Therapeutics website at www.bindtherapeutics.com.
The webcasts will be archived on the BIND Therapeutics website following
the event for one week.
About BIND Therapeutics
BIND Therapeutics is a clinical-stage nanomedicine platform company
developing Accurins, its novel targeted therapeutics. BIND intends to
leverage its medicinal nanoengineering platform to develop a pipeline of
Accurins, initially in oncology, as well as Accurins in collaboration
with biopharmaceutical companies. BIND's lead drug candidate, BIND-014,
is an Accurin that targets PSMA and contains docetaxel, a
clinically-validated and widely used cancer chemotherapy drug. BIND-014
is currently in Phase 2 clinical trials for non-small cell lung cancer
and metastatic castrate resistant prostate cancer.
BIND has announced collaborations with Amgen, Inc., Pfizer Inc. and
AstraZeneca AB to develop Accurins based on therapeutic payloads from
their product pipelines. BINDís platform originated from the pioneering
nanotechnology research at the Massachusetts Institute of Technology and
Brigham and Womenís Hospital/Harvard Medical School of BINDís scientific
founders and directors Dr. Robert Langer and Dr. Omid Farokhzad. For
more information, please visit the company's web site at www.bindtherapeutics.com.
The Yates Network
Gina Nugent, 617-460-3579
Paul Cox, 212-362-1200
Source: BIND Therapeutics, Inc.